Moderate

COVID-19 — assessment & treatment (SARS-CoV-2; viral pneumonia)

covid-19-management · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Acute SARS-CoV-2 infection ranging from mild upper-respiratory illness to viral pneumonia with hypoxaemic respiratory failure. Management is severity-based: antivirals for high-risk outpatients within the early window; dexamethasone (+/- an immunomodulator) only for those needing supplemental oxygen; supportive oxygen/NIV/escalation for hypoxaemia.

Red flags

  • SpO2 <=92% on air or exertional desaturation
  • Rising respiratory rate / work of breathing / silent hypoxia
  • Haemodynamic instability
  • Suspected PE (pleuritic pain, disproportionate hypoxaemia, raised D-dimer)
  • Immunosuppressed or incompletely vaccinated with progressing disease
  • Secondary bacterial/fungal infection

Assessment

Differential diagnosis

  • Influenza and other viral pneumonias
  • Bacterial community-acquired pneumonia / co-infection
  • Pulmonary embolism (raised risk in COVID)
  • Heart failure / fluid overload
  • COPD or asthma exacerbation
  • Pneumocystis jirovecii pneumonia (immunosuppressed)

Investigations

  • SARS-CoV-2 PCR or rapid antigen test
  • Pulse oximetry (+/- exertional desaturation); ABG if hypoxaemic
  • CXR +/- CT; CTPA if PE suspected (consider given prothrombotic state)
  • FBC, U&E, LFTs, CRP; consider ferritin, D-dimer, LDH
  • Bacterial cultures / sputum if secondary infection suspected
  • ECG (QTc baseline), especially before QT-affecting drugs
  • Risk-stratify for progression: age, immunosuppression, comorbidity, vaccination status

Management

  • Assess severity and oxygenation; give controlled oxygen targeting SpO2 ~92-96% (88-92% if chronic hypercapnia risk)
  • Mild, high-risk outpatient within ~5 days of onset: offer an antiviral (nirmatrelvir-ritonavir preferred where no major interactions; alternatives remdesivir or molnupiravir) to reduce progression
  • Hospitalised NEEDING supplemental oxygen: start dexamethasone 6 mg once daily for up to 10 days
  • Consider adding an immunomodulator (tocilizumab OR baricitinib) for rapidly escalating oxygen needs / systemic inflammation, in addition to steroid — do not combine the two immunomodulators
  • Consider remdesivir in hospitalised patients on low-flow oxygen (less benefit once ventilated)
  • Escalate respiratory support: high-flow nasal oxygen, awake proning, NIV/CPAP, then invasive ventilation and ARDS management as needed
  • VTE prophylaxis for all admitted patients (higher thrombotic risk); treat confirmed PE
  • Treat bacterial co-infection only if evidence; do NOT give steroids to patients not needing oxygen

Drugs & doses

Nirmatrelvir 300 mg + ritonavir 100 mg PO twice daily for 5 days — early high-risk outpatients; CHECK drug interactions and renal dose [verify interactions]
Remdesivir 200 mg IV day 1 then 100 mg IV once daily (3 days outpatient / up to 5 days inpatient on oxygen) [verify local protocol]
Molnupiravir 800 mg PO twice daily for 5 days — alternative where preferred agents unsuitable (not in pregnancy) [verify eligibility]
Dexamethasone 6 mg PO/IV once daily for up to 10 days — ONLY if requiring supplemental oxygen
Tocilizumab 8 mg/kg IV (single dose, max ~800 mg; may repeat) — add to steroid for severe/progressing disease [verify local protocol]
Baricitinib 4 mg PO once daily for up to 14 days — alternative immunomodulator to tocilizumab (renal adjustment) [verify local protocol]
Thromboprophylaxis e.g. enoxaparin 40 mg SC once daily (treatment dose if confirmed VTE) [verify weight/renal dose]

Disposition

Discharge mild cases with safety-netting; high-risk outpatients consider early antiviral. Admit for hypoxaemia/oxygen need or clinical concern. Escalate to HDU/ICU for high-flow oxygen, NIV, or ventilation.

Complications & pitfalls

  • Hypoxaemic respiratory failure / ARDS
  • Venous and arterial thromboembolism
  • Secondary bacterial and fungal (incl. aspergillosis) infection
  • Myocardial injury, arrhythmia
  • Acute kidney injury
  • Steroid/immunomodulator-related: hyperglycaemia, infection risk
  • Post-COVID / long-COVID sequelae

Exam pearls

  • Dexamethasone benefits only patients needing supplemental oxygen and may HARM those who do not — withhold if no oxygen requirement (RECOVERY trial; NICE NG191).
  • Give early antivirals to high-risk outpatients within the first ~5 days of symptoms; nirmatrelvir-ritonavir has many drug interactions via ritonavir — check carefully.
  • Tocilizumab or baricitinib (one, not both) added to steroid reduces mortality in severe/progressing disease (RECOVERY; NICE).
  • COVID is prothrombotic — ensure VTE prophylaxis and keep a low threshold to investigate for PE.
  • Evidence and recommendations evolve with variants and vaccination status — verify against current NICE/IDSA/WHO guidance.
  • Awake proning and HFNO can delay/avoid intubation in cooperative hypoxaemic patients.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.